1
|
Rochefort J, Radoi L, Campana F, Fricain JC, Lescaille G. [Oral cavity cancer: A distinct entity]. Med Sci (Paris) 2024; 40:57-63. [PMID: 38299904 DOI: 10.1051/medsci/2023196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2024] Open
Abstract
Oral Squamous cell carcinoma represent the 17th most frequent cancer in the world. The main risk factors are alcohol and tobacco consumption but dietary, familial, genetic, or oral diseases may be involved in oral carcinogenesis. Diagnosis is made on biopsy, but detection remains late, leading to a poor prognosis. New technologies could reduce these delays, notably Artificial Intelligence and the quantitative evaluation of salivary biological markers. Currently, management of oral cancer consists in surgery, which can be mutilating despite possible reconstructions. In the future, immunotherapies could become a therapeutic alternative and the immune microenvironment could constitute a source of prognostic markers.
Collapse
Affiliation(s)
- Juliette Rochefort
- Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe hospitalier Pitié-Salpêtrière, Service de médecine bucco-dentaire, Paris, France - Faculté d'odontologie, université Paris Cité, Paris, France - Sorbonne université, Inserm U.1135, Centre d'immunologie et des maladies infectieuses, CIMI-Paris, Paris, France
| | - Lorédana Radoi
- Faculté d'odontologie, université Paris Cité, Paris, France - Centre de recherche en épidémiologie et santé des populations, Inserm U1018, université Paris Saclay
| | - Fabrice Campana
- Aix Marseille Univ, Assistance Publique-Hôpitaux de Marseille (AP-HM), Timone Hospital, Oral Surgery Department, Marseille, France
| | - Jean-Christophe Fricain
- CHU Bordeaux, Dentistry and Oral Health Department, F-33404 Bordeaux, France - Inserm U1026, université de Bordeaux, Tissue Bioengineering (BioTis), F-33076 Bordeaux, France
| | - Géraldine Lescaille
- Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe hospitalier Pitié-Salpêtrière, Service de médecine bucco-dentaire, Paris, France - Faculté d'odontologie, université Paris Cité, Paris, France - Sorbonne université, Inserm U.1135, Centre d'immunologie et des maladies infectieuses, CIMI-Paris, Paris, France
| |
Collapse
|
2
|
Rochefort J, Karagiannidis I, Baillou C, Belin L, Guillot-Delost M, Macedo R, Le Moignic A, Mateo V, Soussan P, Brocheriou I, Teillaud JL, Dieu-Nosjean MC, Bertolus C, Lemoine FM, Lescaille G. Defining biomarkers in oral cancer according to smoking and drinking status. Front Oncol 2023; 12:1068979. [PMID: 36713516 PMCID: PMC9875375 DOI: 10.3389/fonc.2022.1068979] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Accepted: 12/22/2022] [Indexed: 01/13/2023] Open
Abstract
Introduction Oral Squamous Cell Carcinomas (OSCC) are mostly related to tobacco consumption eventually associated to alcohol (Smoker/Drinker patients: SD), but 25-30% of the patients have no identified risk factors (Non-Smoker/Non-Drinker patients: NSND). We hypothesized that these patients have distinguishable immune profiles that could be useful for prognosis. Materials and Methods Cells present in immune tumor microenvironment (TME) and blood from 87 OSCC HPV-negative patients were analyzed using a multiparameter flow cytometry assay, in a prospective case-control study. Cytokine levels in tumor supernatants and blood were determined by a cytometric bead array (CBA) assay. Results Normal gingiva and blood from healthy donors (HD) were used as controls. A significant increase of granulocytes (p<0.05 for blood), of monocytes-macrophages (p<0.01 for blood) and of CD4+ T cells expressing CD45RO and CCR6 (p<0.001 for blood; p<0.0001 for TME) as well as higher levels of IL-6 (p<0.01 for sera, p<0.05 for tumor supernatant) were observed in SD patients as compared to NSND OSCC patients and HD. High percentages of CD4+ T cells expressing CD45RO and CCR6 cells in tumor tissue (p=0.05) and blood (p=0.05) of SD OSCC patients were also associated with a poorer prognosis while a high percentage of regulatory T cells (Treg) in tumor tissue was associated with a more favorable prognostic factor (p=0.05). Also, a higher percentage of blood CD8+ T lymphocytes among CD45+ cells in NSND patients was associated with a better disease-free survival (p=0.004). Conclusion Granulocytes, monocytes-macrophages, and CD4+ T cells expressing CD45RO and CCR6 in blood and TME as well as serum IL-6 can therefore distinguish OSCC SD and NSND patients. Quantifying the proportion of CD4+ T cells expressing CD45RO and CCR6 and of Treg in SD patients and CD8+ T cells in NSND patients could help defining the prognostic of OSCC patients.
Collapse
Affiliation(s)
- Juliette Rochefort
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France,Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe hospitalier Pitié-Salpêtrière, Department of Odontology, Paris, France,Faculty of Odontology Université Paris Cité, Paris, France,*Correspondence: Juliette Rochefort,
| | - Ioannis Karagiannidis
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | - Claude Baillou
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | - Lisa Belin
- Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Département de Santé Publique, Paris, France
| | - Maude Guillot-Delost
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | - Rodney Macedo
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | - Aline Le Moignic
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | - Véronique Mateo
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | | | - Isabelle Brocheriou
- AP-HP, Groupe hospitalier Pitié-Salpêtrière, Department of Pathology, Paris, France
| | - Jean-Luc Teillaud
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | - Marie-Caroline Dieu-Nosjean
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France
| | - Chloé Bertolus
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France,AP-HP, Groupe hospitalier Pitié-Salpêtrière, Department of Maxillo-Facial Surgery, Paris, France
| | - Francois Michel Lemoine
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France,AP-HP, Groupe hospitalier Pitié-Salpêtrière, Department of Immunology, Paris, France
| | - Géraldine Lescaille
- Sorbonne Université, Inserm U.1135, Center of Immunology and Infectious Diseases (Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris), Paris, France,Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe hospitalier Pitié-Salpêtrière, Department of Odontology, Paris, France,Faculty of Odontology Université Paris Cité, Paris, France
| |
Collapse
|